Experimental design, population dynamics, and diversity in microbial experimental evolution

B Van den Bergh, T Swings, M Fauvart… - … and Molecular Biology …, 2018 - Am Soc Microbiol
In experimental evolution, laboratory-controlled conditions select for the adaptation of
species, which can be monitored in real time. Despite the current popularity of such …

How the evolution of multicellularity set the stage for cancer

AS Trigos, RB Pearson, AT Papenfuss… - British journal of …, 2018 - nature.com
Neoplastic growth and many of the hallmark properties of cancer are driven by the disruption
of molecular networks established during the emergence of multicellularity. Regulatory …

[HTML][HTML] A pan-cancer analysis of enhancer expression in nearly 9000 patient samples

H Chen, C Li, X Peng, Z Zhou, JN Weinstein… - Cell, 2018 - cell.com
The role of enhancers, a key class of non-coding regulatory DNA elements, in cancer
development has increasingly been appreciated. Here, we present the detection and …

Urea cycle dysregulation generates clinically relevant genomic and biochemical signatures

JS Lee, L Adler, H Karathia, N Carmel, S Rabinovich… - Cell, 2018 - cell.com
The urea cycle (UC) is the main pathway by which mammals dispose of waste nitrogen. We
find that specific alterations in the expression of most UC enzymes occur in many tumors …

Altered interactions between unicellular and multicellular genes drive hallmarks of transformation in a diverse range of solid tumors

AS Trigos, RB Pearson… - Proceedings of the …, 2017 - National Acad Sciences
Tumors of distinct tissues of origin and genetic makeup display common hallmark cellular
phenotypes, including sustained proliferation, suppression of cell death, and altered …

Cancer progression as a sequence of atavistic reversions

CH Lineweaver, KJ Bussey, AC Blackburn… - …, 2021 - Wiley Online Library
It has long been recognized that cancer onset and progression represent a type of reversion
to an ancestral quasi‐unicellular phenotype. This general concept has been refined into the …

What are the reasons for continuing failures in cancer therapy? Are misleading/inappropriate preclinical assays to be blamed? Might some modern therapies cause …

R Mirzayans, D Murray - International Journal of Molecular Sciences, 2022 - mdpi.com
Over 50 years of cancer research has resulted in the generation of massive amounts of
information, but relatively little progress has been made in the treatment of patients with solid …

Intratumor heterogeneity and therapy resistance: Contributions of dormancy, apoptosis reversal (anastasis) and cell fusion to disease recurrence

R Mirzayans, D Murray - International journal of molecular sciences, 2020 - mdpi.com
A major challenge in treating cancer is posed by intratumor heterogeneity, with different sub-
populations of cancer cells within the same tumor exhibiting therapy resistance through …

Enhancer-driven lncRNA BDNF-AS induces endocrine resistance and malignant progression of breast cancer through the RNH1/TRIM21/mTOR cascade

X Lin, X Dinglin, S Cao, S Zheng, C Wu, W Chen, Q Li… - Cell reports, 2020 - cell.com
Epigenomic alterations can give rise to various tumor-promoting properties, including
therapeutic resistance of cancer cells. Here, we identify an lncRNA, BDNF-AS, whose …

Somatic mosaicism: on the road to cancer

LC Fernandez, M Torres, FX Real - Nature Reviews Cancer, 2016 - nature.com
Diversity is the basis of fitness selection. Although the genome of an individual is considered
to be largely stable, there is theoretical and experimental evidence—both in model …